Pimozide as an adjuvant to maintenance therapy in chronic schizophrenia.
An open, 12-week study of pimozide (8 mg per day) used concurrently with previous maintenance therapy was carried out to investigate improvements in the social behaviour of 20 chronic schizophrenics. Ward behaviour, work habits and mental status all showed statistically significant improvement after 8 weeks of treatment. The incidence of side-effects was low.
D000328:Adult; D014150:Antipsychotic Agents / Q000627:therapeutic use; D002908:Chronic Disease; D004359:Drug Therapy, Combination; D006801:Humans; D008297:Male; D008875:Middle Aged; D010868:Pimozide / Q000009:adverse effects / Q000627:therapeutic use*; D012559:Schizophrenia / Q000188:drug therapy*
D014150:Antipsychotic Agents; D010868:Pimozide